trending Market Intelligence /marketintelligence/en/news-insights/trending/b5zlqxpdaggusbetk_dnkw2 content esgSubNav
In This List

Ipsen secures EC approval for kidney cancer drug

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Ipsen secures EC approval for kidney cancer drug

France's Ipsen SA said the European Commission approved its drug Cabometyx as a first-line therapy for a type of kidney cancer.

Cabometyx was approved for treating adults with intermediate or poor-risk advanced renal cell carcinoma in all 28 member states of the European Union as well as Norway and Iceland.

In 2016, Ipsen entered a deal with Exelixis for the exclusive rights for the commercialization and development of Cabometyx outside the U.S. and Japan.

The European Commission approval triggered a $50 million payment from Ipsen to Exelixis — $46 million of which was recognized as collaboration revenue in the first quarter.

The U.S. Food and Drug Administration previously expanded its approval of Cabometyx to include treating advanced renal cell carcinoma. The FDA also accepted an application to expand the drug's indication for a type of liver cancer.